Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Apr 10;22(8):3916. doi: 10.3390/ijms22083916

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Twist knockdown sensitizes CisR OC cells to Cis and niraparib (Nira) therapy. (A) The dose response curve of Cis and Nira at 1:1, 2:1 and 1:2 combination ratio on parental, siNC CisR and siTwist CisR OV90 and SKOV3 cells. The cells were co-treated with increase dose of Cis and Nira (0–160 µM) for 72 h and percentage of cell survival was determined by EZ-cytox cell viability kit. (B) Measurement of combination index (CI) using compusyn software. P: parental CisR: cisplatin-resistant; siRNA: small interfering RNA; siNC: non-targeting negative control, siRNA; siTwist: Twist siRNA; DMSO: dimethyl sulfoxide, Cis: cisplatin; Nira; niraparib; Fa: fraction of affected cells.